PHGE: BiomX Inc. Stock

by  •  • Comments Off on PHGE: BiomX Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 18.55
Enterprise Value ($M) 14.83
Book Value ($M) 3.08
Book Value / Share 0.06
Price / Book 6.02
NCAV ($M) -4.32
NCAV / Share -0.08
Price / NCAV -4.30

Profitability (mra)
Return on Invested Capital (ROIC) -1.44
Return on Assets (ROA) -0.63
Return on Equity (ROE) -1.62

Liquidity (mrq)
Quick Ratio 1.58
Current Ratio 1.58

Balance Sheet (mrq) ($M)
Current Assets 17.63
Assets 25.03
Liabilities 21.95
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -25.35
Net Income -26.17
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -21.29
Cash from Investing 1.95
Cash from Financing 2.90

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
03-26 13G/A Cystic Fibrosis Foundation 15.60 104.96
03-25 13G AMR Action Fund, L.P. 5.50
03-22 13D Flynn James E 11.06
03-19 13D/A OrbiMed Israel BioFund GP Limited Partnership 19.90 173.32
02-13 13G/A MMCAP International Inc. SPC 3.22 -31.26
02-02 13G/A Johnson & Johnson 4.60
09-29 13G Centaurus Investments Ltd 6.20
06-23 13G Burbank John Howard III 9.99

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-04 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2023 ☐ TRANSITION REPORT PURSUA
2023-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO
2023-05-15 10-Q Form 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 54,321 168,084 32.32
2024-04-25 25,851 92,885 27.83
2024-04-24 24,691 126,326 19.55
2024-04-23 79,024 221,045 35.75

(click for more detail)

Similar Companies
NNVC – NanoViricides, Inc. OGEN – Oragenics, Inc.
ONDR – Sushi Ginza Onodera, Inc. PLX – Protalix BioTherapeutics, Inc.
PTN – Palatin Technologies, Inc.


Financial data and stock pages provided by
Fintel.io